Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность и переносимость «ступенчатой» терапии при ревматических заболеваниях
Эффективность и переносимость «ступенчатой» терапии при ревматических заболеваниях
Е.С.Цветкова. Эффективность и переносимость «ступенчатой» терапии при ревматических заболеваниях. Consilium Medicum. Неврология (Прил.). 2011; 1: 56-59.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Wallace GL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16.
2. Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992; 263: 136–46.
3. Tilley SL, Coffman TM, Koller BM. Mixed messages: modulation of inflammation and immune responses by prostaglandins and tromboxanes. J Clin Invest 2001; 108: 15–23.
4. Vane GR, Bakchle YS, Bolting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97–120.
5. Насонов Е.Л., Цветкова Е.С. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. арх. 1998; 5: 8–14.
6. Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М., 2000.
7. Needleman P, Isakson P. The discovery and function of COX-2. J Rheumatol 1997; 24 (49): 6–8.
8. DelTacca M, Colucci R, Fornati M, Blandizzi C. Efficacy and tolerability of Meloxicam: nonsteroidal anti-inflammatory drug – selective inhibitor of a cyclo-oxygenase-2. Clin Drug Invest 2002; 22 (12): 799–818.
9. Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 1999; 36: 115–26.
10. Lapicque F, Vergne P, Gouzcau J-I et al. Articular diffusion of Meloxicam after a single oral dose: relationship to cyclo-oxygenaze inhibition in synovial cells. Clin Pharmacocinet 2000; 39: 369–82.
11. Cacace L. Elevated serum CPK after drug injections. N Engl J Med 1972; 287: 309–10.
12. Combe B, Velicitat P, Garson N et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50 (1): S10–6.
13. Auvinet B, Ziller R., Appelboom T et al. Comparison of the Onset and Intensity of Action of Intramuscular Meloxicam and oral Meloxicam in patients with Acute Sciatica. Clin Ther 1995; 17 (6): 78–90.
14. Ghozlan P, Benhardt M, Velicitat P et al. Tolerability of multiple administration of intramuscular Meloxicam: a comparison with of intramuscular Piroxicam in patients with Rheumatoid arthritis or osteoarthritis. Brit J Rheum 1996; 35 (1): 51–5.
15. Bosch H, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and Oral Meloxicam in Patients with Acute Lumbago: a comparison with intramuscular and oral Piroxicam. Curr Med Res Opin 1997; 14 (1): 29–38.
16. Euller-Ziegler L, Velicitat P, Bluhmki E et al. Meloxicam: a rewiew its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 2001; 50 (1): S5–9.
2. Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992; 263: 136–46.
3. Tilley SL, Coffman TM, Koller BM. Mixed messages: modulation of inflammation and immune responses by prostaglandins and tromboxanes. J Clin Invest 2001; 108: 15–23.
4. Vane GR, Bakchle YS, Bolting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97–120.
5. Насонов Е.Л., Цветкова Е.С. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. арх. 1998; 5: 8–14.
6. Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М., 2000.
7. Needleman P, Isakson P. The discovery and function of COX-2. J Rheumatol 1997; 24 (49): 6–8.
8. DelTacca M, Colucci R, Fornati M, Blandizzi C. Efficacy and tolerability of Meloxicam: nonsteroidal anti-inflammatory drug – selective inhibitor of a cyclo-oxygenase-2. Clin Drug Invest 2002; 22 (12): 799–818.
9. Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 1999; 36: 115–26.
10. Lapicque F, Vergne P, Gouzcau J-I et al. Articular diffusion of Meloxicam after a single oral dose: relationship to cyclo-oxygenaze inhibition in synovial cells. Clin Pharmacocinet 2000; 39: 369–82.
11. Cacace L. Elevated serum CPK after drug injections. N Engl J Med 1972; 287: 309–10.
12. Combe B, Velicitat P, Garson N et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50 (1): S10–6.
13. Auvinet B, Ziller R., Appelboom T et al. Comparison of the Onset and Intensity of Action of Intramuscular Meloxicam and oral Meloxicam in patients with Acute Sciatica. Clin Ther 1995; 17 (6): 78–90.
14. Ghozlan P, Benhardt M, Velicitat P et al. Tolerability of multiple administration of intramuscular Meloxicam: a comparison with of intramuscular Piroxicam in patients with Rheumatoid arthritis or osteoarthritis. Brit J Rheum 1996; 35 (1): 51–5.
15. Bosch H, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and Oral Meloxicam in Patients with Acute Lumbago: a comparison with intramuscular and oral Piroxicam. Curr Med Res Opin 1997; 14 (1): 29–38.
16. Euller-Ziegler L, Velicitat P, Bluhmki E et al. Meloxicam: a rewiew its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 2001; 50 (1): S5–9.
Авторы
Е.С.Цветкова
НИИ ревматологии РАМН, Москва
НИИ ревматологии РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.